Page 10 - Response Authority News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Focus on new treatments as Covid vaccine sales fell from $18.4 billion in 2022 to $6.8 billion last year

(Reuters) -Moderna on Thursday reported a surprise fourth-quarter profit, helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot. Moderna posted a profit of $217 million, or 55 cents a share, for the quarter. Moderna Chief Financial Officer James Mock in an interview said the company beat its own forecast because of unexpected deferred revenue of $600 million and cost savings of around $300 million created by the company's effort to adjust its manufacturing output last year.

Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valu...

Moderna reports Q4 2023 revenues of $2.81 billion from Spikevax (COVID-19 vaccine), exceeding expectations.

Negotiations of the multilateral pandemic agreement are on the wrong track. At stake is our chance of preventing the next global infectious crisis from turning into another catastrophe